PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.85%
Negative revenue growth while ADI stands at 7.34%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.35%
Negative gross profit growth while ADI is at 11.33%. Joel Greenblatt would examine cost competitiveness or demand decline.
-11.23%
Negative EBIT growth while ADI is at 36.81%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-11.23%
Negative operating income growth while ADI is at 36.81%. Joel Greenblatt would press for urgent turnaround measures.
-22.75%
Negative net income growth while ADI stands at 10.70%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-21.74%
Negative EPS growth while ADI is at 12.20%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-23.91%
Negative diluted EPS growth while ADI is at 12.50%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.77%
Share reduction while ADI is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.00%
Reduced diluted shares while ADI is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
1.80%
Maintaining or increasing dividends while ADI cut them. John Neff might see a strong edge in shareholder returns.
-34.44%
Negative OCF growth while ADI is at 24.84%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-40.57%
Negative FCF growth while ADI is at 36.36%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
49.18%
10Y revenue/share CAGR under 50% of ADI's 228.00%. Michael Burry would suspect a lasting competitive disadvantage.
130.13%
5Y revenue/share CAGR 1.25-1.5x ADI's 88.70%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
30.62%
3Y revenue/share CAGR 1.25-1.5x ADI's 25.50%. Bruce Berkowitz might see better product or regional expansions than the competitor.
101.41%
10Y OCF/share CAGR under 50% of ADI's 514.83%. Michael Burry would worry about a persistent underperformance in cash creation.
146.61%
5Y OCF/share CAGR 1.25-1.5x ADI's 100.55%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
69.41%
3Y OCF/share CAGR above 1.5x ADI's 19.31%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
323.19%
Net income/share CAGR at 50-75% of ADI's 441.50%. Martin Whitman might question if the firm’s product or cost base lags behind.
1889.18%
5Y net income/share CAGR above 1.5x ADI's 565.40%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
68.97%
3Y net income/share CAGR above 1.5x ADI's 44.06%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
181.93%
Below 50% of ADI's 398.65%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
25.48%
5Y equity/share CAGR 1.25-1.5x ADI's 21.28%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
12.20%
3Y equity/share CAGR above 1.5x ADI's 4.20%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
91.76%
Dividend/share CAGR of 91.76% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
106.54%
Dividend/share CAGR of 106.54% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
88.39%
Below 50% of ADI's 304.38%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-1.01%
Firm’s AR is declining while ADI shows 12.76%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.95%
Inventory is declining while ADI stands at 1.88%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.29%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
1.11%
Positive BV/share change while ADI is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
-0.72%
Our R&D shrinks while ADI invests at 4.61%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.93%
We cut SG&A while ADI invests at 3.94%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.